For virologically suppressed adult patients with HIV-1. See Full Indication.
JULUCA | Clinical Trials
Trial Design & Baseline Characteristics
SWORD 1 & 2: Two identically designed, Phase 3 trials in treatment-experienced, virologically suppressed adult patients with HIV-1

Virologic Suppression & Resistance Results
Pooled virologic response and resistance results through 100 weeks

Adverse Reactions
Adverse events and rates of discontinuation due to adverse events at 100 weeks

Patient-Reported Outcomes
Learn about rates of treatment satisfaction and symptom distress at 100 weeks after switching to JULUCA

Lipid and Fracture Data and a DEXA Substudy
Learn more about effect on lipids, incidence of fractures, and change in BMD with JULUCA

BMD=bone mineral density; DEXA=dual-energy X-ray absorptiometry.
DGRWCNT190009